Harbor Capital Advisors Inc. Takes Position in Abivax SA Sponsored ADR $ABVX

Harbor Capital Advisors Inc. bought a new position in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 8,849 shares of the company’s stock, valued at approximately $1,193,000.

Several other institutional investors have also bought and sold shares of ABVX. Jefferies Financial Group Inc. acquired a new position in Abivax during the third quarter worth $38,827,000. Kennedy Capital Management LLC boosted its stake in shares of Abivax by 7.1% in the 2nd quarter. Kennedy Capital Management LLC now owns 241,188 shares of the company’s stock valued at $1,845,000 after purchasing an additional 15,997 shares in the last quarter. Federated Hermes Inc. bought a new stake in shares of Abivax in the 3rd quarter worth about $8,448,000. Persistent Asset Partners Ltd bought a new stake in shares of Abivax in the 3rd quarter worth about $815,000. Finally, Atika Capital Management LLC acquired a new stake in shares of Abivax during the 3rd quarter worth about $5,858,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ABVX shares. Citizens Jmp lifted their price target on shares of Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a report on Tuesday, December 16th. Barclays raised their price objective on shares of Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th. Morgan Stanley lifted their target price on shares of Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. BTIG Research restated a “buy” rating and set a $150.00 price target on shares of Abivax in a research report on Wednesday, February 25th. Finally, Guggenheim reaffirmed a “buy” rating and set a $175.00 price target on shares of Abivax in a report on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.15.

Abivax Stock Performance

Shares of NASDAQ ABVX opened at $118.37 on Monday. Abivax SA Sponsored ADR has a 1-year low of $4.77 and a 1-year high of $148.83. The company has a 50-day moving average of $117.64 and a two-hundred day moving average of $112.34. The company has a market cap of $9.37 billion, a PE ratio of -22.04 and a beta of 1.68.

Abivax (NASDAQ:ABVX) last released its quarterly earnings results on Saturday, February 14th. The company reported ($1.20) EPS for the quarter. The firm had revenue of $0.52 million for the quarter. As a group, equities research analysts forecast that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.